Recent advances in targeted drug therapy for hepatocellular carcinoma
10.3969/j.issn.1001-5256.2018.02.046
- VernacularTitle:靶向药物治疗肝细胞癌的最新进展
- Author:
Yongqiang FAN
1
;
Shengli DONG
Author Information
1. 山西医科大学第二临床医学院普外科
- Keywords:
carcinoma,hepatocellular;
targeted drug;
drug therapy;
clinical trial;
review
- From:
Journal of Clinical Hepatology
2018;34(2):424-428
- CountryChina
- Language:Chinese
-
Abstract:
More and more clinical trials have proved the efficacy of targeted drugs in the treatment of hepatocellular carcinoma (HCC).With the development of science and technology,more and more targeted drugs have appeared.In recent years,targeted drugs such as regorafenib and ramucirumab have shown great potential in related clinical trials.In addition,there are ongoing clinical trials for second-linecandidate drugs,such as c-Met inhibitors tivantinib and cabozantinib and a VEGFR-2 inhibitor ramucirumab.This article summarizes the advances in targeted drug therapy for HCC and related trial data,which provides a reference for further clinical trials and treatment.
